Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 7/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAG | P20916 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23490967 | 0.87 | CD69 (0.45) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL18022304 | 0.83 | CD69 (0.47) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL23490870 | 0.82 | CD69 (0.48) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL20122239 | 0.81 | LGALS3 (0.58) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL20121276 | 0.81 | LGALS3 (0.58) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL15333778 | 0.81 | LGALS3 (0.58) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL7147918 | 0.81 | LGALS8 (0.55) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL19503330 | 0.81 | LGALS8 (0.55) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL21572847 | 0.81 | LGALS8 (0.55) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL7147921 | 0.81 | LGALS8 (0.55) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171561-A1 | METHOD FOR ANALYSIS OF CHONDROITIN SULFATE | JCR PHARMACEUTICALS CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171561-A1 | METHOD FOR ANALYSIS OF CHONDROITIN SULFATE | NEFM, SI, MMP13 | CD69 298/4885LGALS3 1412/4885LGALS7; LGALS7B 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.